UBS Reaffirms Buy Rating on ASML After Quarterly Results

UBS reaffirmed its Buy rating on ASML, whose latest reported quarterly results included earnings of $8.65 per share and revenue of $10.62 billion. Other analysts were also broadly positive, leaving ASML with a consensus Moderate Buy rating and an average price target of about $1,970, although several firms maintained Hold or Sell ratings.
Where do you stand?
How it spread
Claim check
What each side asserts, disputes — or leaves out entirely.
Where do you land?
Whose framing of this story rings truest to you?





